Marker Therapeutics Enters Material Definitive Agreement
Ticker: MRKR · Form: 8-K · Filed: Feb 26, 2024 · CIK: 1094038
| Field | Detail |
|---|---|
| Company | Marker Therapeutics, Inc. (MRKR) |
| Form Type | 8-K |
| Filed Date | Feb 26, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $750,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, corporate-event
TL;DR
**Marker Therapeutics just inked a new material agreement, signaling potential big changes ahead!**
AI Summary
Marker Therapeutics, Inc. (MRKR) filed an 8-K on February 22, 2024, to report the entry into a material definitive agreement. The filing indicates a significant corporate event, likely a new contract or partnership, that could impact the company's financial and operational outlook. The specific details of the agreement are not fully disclosed in the provided excerpt but are categorized under 'Entry into a Material Definitive Agreement' and 'Financial Statements and Exhibits'.
Why It Matters
This filing signals a new, potentially impactful business arrangement for Marker Therapeutics, which could influence its future revenue streams, strategic direction, or operational costs.
Risk Assessment
Risk Level: medium — The filing indicates a material agreement but lacks specific details, making the exact impact and associated risks unclear without further information.
Key Numbers
- 2024-02-22 — Date of Event (The date the material definitive agreement was entered into.)
- 001-37939 — SEC File Number (Marker Therapeutics' SEC file number.)
Key Players & Entities
- Marker Therapeutics, Inc. (company) — Registrant
- February 22, 2024 (date) — Date of earliest event reported
- Delaware (company) — State of incorporation
- 001-37939 (dollar_amount) — Commission File Number
- Houston, Texas (company) — Principal executive offices location
FAQ
What is the primary purpose of this 8-K filing by Marker Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report the 'Entry into a Material Definitive Agreement' and 'Financial Statements and Exhibits' as of February 22, 2024.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 22, 2024.
What is the state of incorporation for Marker Therapeutics, Inc.?
Marker Therapeutics, Inc. is incorporated in Delaware.
What is the Commission File Number for Marker Therapeutics, Inc.?
The Commission File Number for Marker Therapeutics, Inc. is 001-37939.
Where are Marker Therapeutics, Inc.'s principal executive offices located?
Marker Therapeutics, Inc.'s principal executive offices are located at 9350 Kirby Drive, Suite 300, Houston, Texas 77054.
Filing Stats: 669 words · 3 min read · ~2 pages · Grade level 11.5 · Accepted 2024-02-26 07:58:51
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share MRKR The Nasdaq Stock Mar
- $750,000 — Order #1 are not anticipated to exceed $750,000. The services will cover the anticipate
Filing Documents
- tm247177d1_8k.htm (8-K) — 24KB
- 0001104659-24-027293.txt ( ) — 192KB
- mrkr-20240222.xsd (EX-101.SCH) — 3KB
- mrkr-20240222_lab.xml (EX-101.LAB) — 33KB
- mrkr-20240222_pre.xml (EX-101.PRE) — 22KB
- tm247177d1_8k_htm.xml (XML) — 3KB
01. ENTRY INTO A MATERIAL
ITEM 1.01. ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT On February 22, 2024, Marker Therapeutics, Inc. (the "Company") entered into a Master Services Agreement for Product Supply (the "Agreement") with Cell Ready LLC ("Cell Ready"). Cell Ready, which is owned by one of the Company's directors and shareholders, Mr. John Wilson, is a contract development and manufacturing organization (CDMO). Pursuant to the Agreement, the Company may contract with Cell Ready for the provision of various products and services from time to time by entering into work orders with Cell Ready. If the services involve the supply of product, Cell Ready is required to supply such product in conformance with the product requirements set forth in the applicable work order(s). The Agreement contains customary representations, warranties and indemnification provision. The initial term of the Agreement is three years and may be extended upon the mutual written agreement of the parties. Either party may terminate the Agreement (a) for material breach by the other party if such breach has not been cured within 30 days following notice of termination or (b) if the other party is the subject of an insolvency event. Also on February 22, 2024, the Company entered into Work Order #1 under the Agreement, pursuant to which Cell Ready will provide the Company with GMP drug product for Marker MT-401 and/or MT-601. The services include the delivery of final drug product and quality control testing. The Company also requested Cell Ready to provide general support services in connection therewith. The total projected sum (inclusive of taxes) for the services under Work Order #1 are not anticipated to exceed $750,000. The services will cover the anticipated manufacturing costs for the first quarter of 2024. Additional Work Orders are expected to be generated for the remainder of 2024.
01. FINANCIAL STATEMENTS AND EXHIBITS
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Marker Therapeutics, Inc. Dated: February 26, 2024 By: /s/ Juan Vera Juan Vera President and Chief Executive Officer